Ten post jest także dostępny w języku:
Sanofi-Aventis has appointed Agnieszka Grzybowska-Zalewska to the position of CEO. Previously, since 2013, she served as CEO of Sanofi Genzyme in Poland, one of Sanofi’s core business units. Magdalena Kruszewska, previously CEO of Sanofi in Poland, moves to the global structure.
Magdalena Kruszewska, who has been promoted to head the newly created Central and Southern Europe area within Sanofi
‘s global structure, will hand over the reins to Grzybowska-Zalewska, who will also continue to be responsible for General Medicines’ mature medicines portfolio in Central Europe. The new Sanofi region for Central and Southern Europe consists of Poland, Ukraine, Czech Republic, Hungary, Romania, Greece and Israel.
Agnieszka Grzybowska-Zalewska has worked in the pharmaceutical industry for over 20 years in a wide range of areas – management, marketing or sales. Since 2013 she was CEO of Sanofi Genzyme in Poland – one of Sanofi’s core business groups, which provides innovative therapies for rare diseases, oncology, immunology or multiple sclerosis.
Since 2013 she has been CEO of Sanofi Genzyme in Poland, one of Sanofi
‘s core business groups that delivers breakthrough medicines for rare diseases, cancer, immunology or multiple sclerosis. Previously, she was responsible for the successful merger of Genzyme’s business with Sanofi in Poland, and held leadership positions in sales and marketing, where she successfully developed the rare disease drug portfolio. Janssen-Cilag was her first step in a career in the pharmaceutical sector, which she started in 1998. Agnieszka Grzybowska-Zalewska is a graduate of the Faculty of Biology at the University of Gdansk and the Faculty of Pharmacy at the Medical University of Gdansk.
Sanofi is a global biopharmaceutical company. Its shares are listed on stock exchanges in Paris and New York. In Rzeszow there is one of 74 Sanofi plants in the world. In Poland it employs over 900 people. Agnieszka Grzybowska-Zalewska said that over the past two years Sanofi has been transforming itself into a biopharmaceutical company as part of its Play to Win strategy, developing breakthrough drugs in areas where patients previously had no therapeutic options. The company will continue this strategy in Poland, working with a strong local team.